BRCA1 and cancer: However, different genes A dominate the SL interactions within the individual cancers – e.g. CDH1 (99.5 %) for breast, PTEN (78.4 %) and BRCA2 (16.8 %) for prostate and BRCA1 (17.9 %) and TP53 (16.2 %) for ovarian cancers at p < 0.01, as shown in Fig. 1b.